Drug discovery targeting epigenetic codes: The great potential of UHRF1, which links DNA methylation and histone modifications, as a drug target in cancers and toxoplasmosis

Biochemical Pharmacology

Volumn 78, Issue 10, 2009, Pages 1279-1288

  Unoki, Motoko ^a   Brunet, Julie ^b   Mousli, Marc ^b  

^a INST OF PHYS AND CHEMICAL RESEARCH   (Japan)

^b UNIVERSITÉ DE STRASBOURG   (France)

Author keywords

Cancer vaccine; Molecular targeted therapy; Toxoplasmosis; UHRF1

Indexed keywords

ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; AZACITIDINE; CANCER VACCINE; CYCLIN DEPENDENT KINASE INHIBITOR 1; HISTONE; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE INHIBITOR; HISTONE H3; PACLITAXEL; PROTEIN; PROTEIN P53; PYRIMETHAMINE; SMALL INTERFERING RNA; SPIRAMYCIN; SULFADIAZINE; TAMOXIFEN; TRANSCRIPTION FACTOR E2F1; TRASTUZUMAB; UBIQUITIN LIKE WITH PHD AND RING FINGER DOMAIN 1; UNCLASSIFIED DRUG; VORINOSTAT;

ARTICLE; BLINDNESS; BREAST CANCER; CARCINOGENESIS; CELL CYCLE G1 PHASE; CELL CYCLE REGULATION; CELL CYCLE S PHASE; CELL GROWTH; CHROMATIN STRUCTURE; DAUGHTER CELL; DNA METHYLATION; DNA STRAND; DOWN REGULATION; DRUG DESIGN; DRUG TARGETING; EPIGENETICS; GENETIC CODE; HETEROCHROMATIN; HUMAN; IMMUNE SYSTEM; MYELODYSPLASTIC SYNDROME; NEOPLASM; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN MODIFICATION; SKIN LYMPHOMA; SUBRETINAL NEOVASCULARIZATION; T CELL LYMPHOMA; TOXOPLASMA GONDII; TOXOPLASMOSIS; UBIQUITINATION; UNSPECIFIED SIDE EFFECT; UPREGULATION;

EID: 70349463160     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2009.05.035     Document Type: Note

References (65)

1. Arita K., Ariyoshi M., Tochio H., Nakamura Y., and Shirakawa M. Recognition of hemi-methylated DNA by the SRA protein UHRF1 by a base-flipping mechanism. Nature 455 (2008) 818-821
2. Hashimoto H., Horton J.R., Zhang X., Bostick M., Jacobsen S.E., and Cheng X. The SRA domain of UHRF1 flips 5-methylcytosine out of the DNA helix. Nature 455 (2008) 826-829
3. Avvakumov G.V., Walker J.R., Xue S., Li Y., Duan S., Bronner C., et al. Structural basis for recognition of hemi-methylated DNA by the SRA domain of human UHRF1. Nature 455 (2008) 822-825
4. Sharif J., Muto M., Takebayashi S., Suetake I., Iwamatsu A., Endo T.A., et al. The SRA protein Np95 mediates epigenetic inheritance by recruiting Dnmt1 to methylated DNA. Nature 450 (2007) 908-912
5. Arima Y., Hirota T., Bronner C., Mousli M., Fujiwara T., Niwa S., et al. Down-regulation of nuclear protein ICBP90 by p53/p21Cip1/WAF1-dependent DNA-damage checkpoint signals contributes to cell cycle arrest at G1/S transition. Genes Cells 9 (2004) 131-142
6. Brunet J., Pfaff A.W., Abidi A., Unoki M., Nakamura Y., Guinard M., et al. Toxoplasma gondii exploits UHRF1 and induces host cell cycle arrest at G2 to enable its proliferation. Cell Microbiol 10 (2008) 908-920
7. Jenkins Y., Markovtsov V., Lang W., Sharma P., Pearsall D., Warner J., et al. Critical role of the ubiquitin ligase activity of UHRF1, a nuclear RING finger protein, in tumor cell growth. Mol Biol Cell 16 (2005) 5621-5629
8. Mousli M., Hopfner R., Abbady A.Q., Monte D., Jeanblanc M., Oudet P., et al. ICBP90 belongs to a new family of proteins with an expression that is deregulated in cancer cells. Br J Cancer 89 (2003) 120-127
9. Unoki M., Nishidate T., and Nakamura Y. ICBP90, an E2F-1 target, recruits HDAC1 and binds to methyl-CpG through its SRA domain. Oncogene 23 (2004) 7601-7610
10. Oba-Shinjo S.M., Bengtson M.H., Winnischofer S.M., Colin C., Vedoy C.G., de Mendonca Z., et al. Identification of novel differentially expressed genes in human astrocytomas by cDNA representational difference analysis. Brain Res Mol Brain Res 140 (2005) 25-33
11. Crnogorac-Jurcevic T., Gangeswaran R., Bhakta V., Capurso G., Lattimore S., Akada M., et al. Proteomic analysis of chronic pancreatitis and pancreatic adenocarcinoma. Gastroenterology 129 (2005) 1454-1463
12. Ho C., Ochsenbein A.F., Gautschi O., and Davies A.M. Early clinical trial experience with vaccine therapies in non-small-cell lung cancer. Clin Lung Cancer 9 Suppl. 1 (2008) S20-S27
13. Karagianni P., Amazit L., Qin J., and Wong J. ICBP90, a novel methyl K9 H3 binding protein linking protein ubiquitination with heterochromatin formation. Mol Cell Biol 28 (2008) 705-717
14. Kim J.K., Esteve P.O., Jacobsen S.E., and Pradhan S. UHRF1 binds G9a and participates in p21 transcriptional regulation in mammalian cells. Nucleic Acids Res 37 (2009) 493-505
15. Achour M., Jacq X., Ronde P., Alhosin M., Charlot C., Chataigneau T., et al. The interaction of the SRA domain of ICBP90 with a novel domain of DNMT1 is involved in the regulation of VEGF gene expression. Oncogene 27 (2008) 2187-2197
16. Dillon N. Heterochromatin structure and function. Biol Cell 96 (2004) 631-637
17. Citterio E., Papait R., Nicassio F., Vecchi M., Gomiero P., Mantovani R., et al. Np95 is a histone-binding protein endowed with ubiquitin ligase activity. Mol Cell Biol 24 (2004) 2526-2535
18. Weake V.M., and Workman J.L. Histone ubiquitination: triggering gene activity. Mol Cell 29 (2008) 653-663
19. Clouaire T., and Stancheva I. Methyl-CpG binding proteins: specialized transcriptional repressors or structural components of chromatin?. Cell Mol Life Sci 65 (2008) 1509-1522
20. Bronner C., Achour M., Arima Y., Chataigneau T., Saya H., and Schini-Kerth V.B. The UHRF family: oncogenes that are drugable targets for cancer therapy in the near future?. Pharmacol Ther 115 (2007) 419-434
21. Mori T., Li Y., Hata H., and Kochi H. NIRF is a ubiquitin ligase that is capable of ubiquitinating PCNP, a PEST-containing nuclear protein. FEBS Lett 557 (2004) 209-214
22. Ballestar E., and Wolffe A.P. Methyl-CpG-binding proteins. Targeting specific gene repression. Eur J Biochem 268 (2001) 1-6
23. Daniel J.M., Spring C.M., Crawford H.C., Reynolds A.B., and Baig A. The p120(ctn)-binding partner Kaiso is a bi-modal DNA-binding protein that recognizes both a sequence-specific consensus and methylated CpG dinucleotides. Nucleic Acids Res 30 (2002) 2911-2919
24. Fuks F., Hurd P.J., Wolf D., Nan X., Bird A.P., and Kouzarides T. The methyl-CpG-binding protein MeCP2 links DNA methylation to histone methylation. J Biol Chem 278 (2003) 4035-4040
25. Sarraf S.A., and Stancheva I. Methyl-CpG binding protein MBD1 couples histone H3 methylation at lysine 9 by SETDB1 to DNA replication and chromatin assembly. Mol Cell 15 (2004) 595-605
26. Fuks F., Hurd P.J., Deplus R., and Kouzarides T. The DNA methyltransferases associate with HP1 and the SUV39H1 histone methyltransferase. Nucleic Acids Res 31 (2003) 2305-2312
27. Hussain S.P., and Harris C.C. Molecular epidemiology and carcinogenesis: endogenous and exogenous carcinogens. Mutat Res 462 (2000) 311-322
28. Nishidate T., Katagiri T., Lin M.L., Mano Y., Miki Y., Kasumi F., et al. Genome-wide gene-expression profiles of breast-cancer cells purified with laser microbeam microdissection: identification of genes associated with progression and metastasis. Int J Oncol 25 (2004) 797-819
29. Unoki M, Kelly JD, Neal DE, Ponder BAJ, Nakamura Y, Hamamoto R. UHRF1 is a novel molecular marker for diagnosis and the prognosis of bladder cancer. Br J Cancer, in press. Online on Jun 2, 2009. [Epub ahead of print].
30. Lorenzato M., Caudroy S., Bronner C., Evrard G., Simon M., Durlach A., et al. Cell cycle and/or proliferation markers: what is the best method to discriminate cervical high-grade lesions?. Hum Pathol 36 (2005) 1101-1107
31. Rhodes D.R., Kalyana-Sundaram S., Mahavisno V., Varambally R., Yu J., Briggs B.B., et al. Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. Neoplasia 9 (2007) 166-180
32. Mori T., Li Y., Hata H., Ono K., and Kochi H. NIRF, a novel RING finger protein, is involved in cell-cycle regulation. Biochem Biophys Res Commun 296 (2002) 530-536
33. Li Y., Mori T., Hata H., Homma Y., and Kochi H. NIRF induces G1 arrest and associates with Cdk2. Biochem Biophys Res Commun 319 (2004) 464-468
34. Shen Y. Advances in the development of siRNA-based therapeutics for cancer. IDrugs 11 (2008) 572-578
35. Leung R.K., and Whittaker P.A. RNA interference: from gene silencing to gene-specific therapeutics. Pharmacol Ther 107 (2005) 222-239
36. Hashimoto S., Hirose M., Hashimoto A., Morishige M., Yamada A., Hosaka H., et al. Targeting AMAP1 and cortactin binding bearing an atypical src homology 3/proline interface for prevention of breast cancer invasion and metastasis. Proc Natl Acad Sci U S A 103 (2006) 7036-7041
37. Hopfner R., Mousli M., Jeltsch J.M., Voulgaris A., Lutz Y., Marin C., et al. ICBP90, a novel human CCAAT binding protein, involved in the regulation of topoisomerase IIalpha expression. Cancer Res 60 (2000) 121-128
38. Hollman R.E., and Greig J.R. Toxoplasmosis in immunocompromised patients. Curr Opin Infect Dis 10 (1997) 281-284
39. Sinai A.P., Payne T.M., Carmen J.C., Hardi L., Watson S.J., and Molestina R.E. Mechanisms underlying the manipulation of host apoptotic pathways by Toxoplasma gondii. Int J Parasitol 34 (2004) 381-391
40. Pfefferkorn E.R., Eckel M., and Rebhun S. Interferon-gamma suppresses the growth of Toxoplasma gondii in human fibroblasts through starvation for tryptophan. Mol Biochem Parasitol 20 (1986) 215-224
41. Fox B.A., Gigley J.P., and Bzik D.J. Toxoplasma gondii lacks the enzymes required for de novo arginine biosynthesis and arginine starvation triggers cyst formation. Int J Parasitol 34 (2004) 323-331
42. Chaudhary K., Darling J.A., Fohl L.M., Sullivan Jr. W.J., Donald R.G., Pfefferkorn E.R., et al. Purine salvage pathways in the apicomplexan parasite Toxoplasma gondii. J Biol Chem 279 (2004) 31221-31227
43. Pfaff A.W., and Candolfi E. New insights in toxoplasmosis immunology during pregnancy. Perspective for vaccine prevention. Parassitologia 50 (2008) 55-58
44. Montoya J.G., and Liesenfeld O. Toxoplasmosis. Lancet 363 (2004) 1965-1976
45. Dubey J.P., Lindsay D.S., and Speer C.A. Structures of Toxoplasma gondii tachyzoites, bradyzoites, and sporozoites and biology and development of tissue cysts. Clin Microbiol Rev 11 (1998) 267-299
46. Mortensen P.B., Norgaard-Pedersen B., Waltoft B.L., Sorensen T.L., Hougaard D., and Yolken R.H. Early infections of Toxoplasma gondii and the later development of schizophrenia. Schizophr Bull 33 (2007) 741-744
47. Cohen B.A. Neurologic manifestations of toxoplasmosis in AIDS. Semin Neurol 19 (1999) 201-211
48. Molestina R.E., El-Guendy N., and Sinai A.P. Infection with Toxoplasma gondii results in dysregulation of the host cell cycle. Cell Microbiol 10 (2008) 1153-1165
49. Leng J., Butcher B.A., Egan C.E., Abdallah D.S., and Denkers E.Y. Toxoplasma gondii prevents chromatin remodeling initiated by TLR-triggered macrophage activation. J Immunol 182 (2009) 489-497
50. Tschop K., and Engeland K. Cell cycle-dependent transcription of cyclin B2 is influenced by DNA methylation but is independent of methylation in the CDE and CHR elements. FEBS J 274 (2007) 5235-5249
51. Laliberte J., and Carruthers V.B. Host cell manipulation by the human pathogen Toxoplasma gondii. Cell Mol Life Sci 65 (2008) 1900-1915
52. Goebel S., Gross U., and Luder C.G. Inhibition of host cell apoptosis by Toxoplasma gondii is accompanied by reduced activation of the caspase cascade and alterations of poly(ADP-ribose) polymerase expression. J Cell Sci 114 (2001) 3495-3505
53. Kim L., and Denkers E.Y. Toxoplasma gondii triggers Gi-dependent PI 3-kinase signaling required for inhibition of host cell apoptosis. J Cell Sci 119 (2006) 2119-2126
54. Molestina R.E., and Sinai A.P. Detection of a novel parasite kinase activity at the Toxoplasma gondii parasitophorous vacuole membrane capable of phosphorylating host IkappaBalpha. Cell Microbiol 7 (2005) 351-362
55. Butcher B.A., Kim L., Panopoulos A.D., Watowich S.S., Murray P.J., and Denkers E.Y. IL-10-independent STAT3 activation by Toxoplasma gondii mediates suppression of IL-12 and TNF-alpha in host macrophages. J Immunol 174 (2005) 3148-3152
56. Dubey J.P. The history of Toxoplasma gondii-the first 100 years. J Eukaryot Microbiol 55 (2008) 467-475
57. Lavine M.D., and Arrizabalaga G. Induction of mitotic S-phase of host and neighboring cells by Toxoplasma gondii enhances parasite invasion. Mol Biochem Parasitol 164 (2009) 95-99
58. Estes R., Vogel N., Mack D., and McLeod R. Paclitaxel arrests growth of intracellular Toxoplasma gondii. Antimicrob Agents Chemother 42 (1998) 2036-2040
59. Coppens I., Dunn J.D., Romano J.D., Pypaert M., Zhang H., Boothroyd J.C., et al. Toxoplasma gondii sequesters lysosomes from mammalian hosts in the vacuolar space. Cell 125 (2006) 261-274
60. Schiff P.B., Fant J., and Horwitz S.B. Promotion of microtubule assembly in vitro by taxol. Nature 277 (1979) 665-667
61. Lahmar I. Cytokine profiles in toxoplasmic and viral uveitis. J Infect Dis 199 (2009) 1239-1249
62. Tolentino M.J., Brucker A.J., Fosnot J., Ying G.S., Wu I.H., Malik G., et al. Intravitreal injection of vascular endothelial growth factor small interfering RNA inhibits growth and leakage in a nonhuman primate, laser-induced model of choroidal neovascularization. Retina 24 (2004) 660
63. Jeanblanc M., Mousli M., Hopfner R., Bathami K., Martinet N., Abbady A.Q., et al. The retinoblastoma gene and its product are targeted by ICBP90: a key mechanism in the G1/S transition during the cell cycle. Oncogene 24 (2005) 7337-7345
64. Bostick M., Kim J.K., Esteve P.O., Clark A., and Pradhan S. Jacobsen SE. UHRF1 plays a role in maintaining DNA methylation in mammalian cells. Science 317 (2007) 1760-1764
65. Mistry H., Gibson L., Yun J.W., Sarras H., and Tamblyn L. McPherson JP. Interplay between Np95 and Eme1 in the DNA damage response. Biochem Biophys Res Commun 375 (2008) 321-325